Control Group:Benzydamine Hydrochloride spray by mouth three times daily for 20 days.
Follow up: The patients will be recalled at one week interval for 20 days.

Intervention group: 90% solcoseryl and 10% pumpkin seed oil spray by mouth three times daily for 20 days

Mucositis Oral

Patients will rinse by mouth three times daily for 20 days

Benzydamine Hydrochloride

Patients will receive by mouth three times daily for 20 days

Solcoseryl and pumpkin seed oil

Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

Clinical Evaluation of Solcosreyl and Pumpkin Seed Oil Versus Benzydamine Hydrochloride in Management of Patients With Chemotherapy and Radiotherapy Induced Oral Mucositis

World Health Organization (WHO)scale.It is graded from 0 to 4. If the patient has no signs and symptoms, it is graded as 0. If the patient has painless ulcers, edema, or mild soreness, it is graded as 1. If there is painful erythema, edema, or ulcers but able to eat, it is graded as 2. If there is painful erythema, edema, or ulcers but unable eat, it is graded as 3. If there a requirement for parenteral or enteral support, it is graded as 4

Patient-Reported Oral Mucositis( PROMS scale) will measure Quality of life .The PROMS scale consists of 10, 100-mm horizontal visual analogue scales addressing oral functions affected by oral mucositis. Participants will be asked to mark a point on the line that best represents their present intra-oral condition.During the baseline examination and prior to their completion of the actual PROMS scale questionnaire, participants were subjected to a few training test-visual analogue scale questions focused on simple everyday topics to familiarize them with the concept of visual analogue scale assisted measurements. The participants will complete the PROMS questionnaire thrice; baseline, after the first week, and at the end of the study after the second week.

Ghada zaki

assistant lecturer at el ahram canadian university

Treatment will be placed in identical spray containers

Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection and 40-minute intravenous infusion of 0.9% sodium chloride.

Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.5 mg/kg of ketamine and a 40-minute intravenous infusion of 0.9% sodium chloride.

Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.9% sodium chloride and a 40-minute intravenous infusion of 0.5 mg/kg ketamine.

Postpartum Depression

Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).

Ketamine 50 MG/ML

Administration of 0.9% Sodium Chloride (N/S)

Control

Washington University in St. Louis

Ketamine to Prevent PPD After Cesarean

Postpartum Depression After Cesarean Delivery: Ketamine as a Preventative Intervention: A Feasibility Pilot-study

Establish a sufficient burden of disease (>10%) in our population to warrant a full RCT

Establish a recruitment rate of greater than 50% to confirm the feasibility of conducting an RCT in our population

Ensure that the design of assessments and data collection make it possible to achieve a complete dataset in >90% of participants

Ascertain that neither of the chosen routes of administration of ketamine are intolerable to patients, as defined as the incidence of one or more severe side effects experienced by >10% of participants in that study arm.

Intraoperative supplementary analgesia in morphine milligram equivalents

Incidence of systolic BP less than 90 mmHg

Reported maximal level of intraoperative pain on the numerical rating scale 0 - 10

Incidence and severity (mild, moderate or severe) of nausea, vomiting, pruritus, dizziness, sedation, shivering, anxiety, euphoria, hallucinations, amnesia, blurred vision, diplopia, nystagmus

Validated measure of depressive symptoms in the postpartum period

Systolic hypertension of greater than 140 mmHg

Validated scale for anxiety. Score out of 21.

Washington University School of Medicine

Participants will be randomised to one of three groups (two interventional and one control).

The ketamine and placebo study injectates (subcutaneous and intravenous) will be prepared, in way that does not allow differentiation, by pharmacy staff who are otherwise uninvolved in the study. Participants will be allocated to groups using a random sequence generator. The patients, investigators and outcome assessors will remain unaware of their group until data collection is complete for all participants.

aspartic acid/hemorrhage

Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

Ketamine to Prevent PPD After Cesarean

Шинжлэх ухаанаар баталгаажсан эмийн өвс ургамлын бүрэн мэдээллийн сан